- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04536805
Relapse in Previously Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiated by Metformin (REPAIR)
Relapse in Previously Irradiated Prostate Bed : a Phase I/II Study of Stereotactic Ablative Reirradiation Potentiated by Metformin
Study Overview
Status
Conditions
Detailed Description
The purpose of this escalation study is, first to select the recommended dose of re-irradiation SBRT in combination with Metformin (based on treatment toxicity monitoring) and then to estimate the efficacy of re-irradiation SBRT in combination with Metformin.
Five or six fractions, at a level of 5 or 6 Gray (Gy) per session (either 5 x 6 Gy, 6 x 6 Gy, or 5 x 5 Gy), will be delivered over a maximum of 12 days (from day 1 to day 10 or 12) to provide a total dose of 25 to 36 Gy.
Patient receive oral Metformin treatment from Day -15 and Day 75.
Patient will be followed for 5 years: patients visits will be planned at week 2; 4; 8; 12; and month M6; M9; M12; M18; M24; M36; 4 years and 5 years.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Nadia ALLAM, PhD
- Phone Number: +33 2 40 67 98 26
- Email: nadia.allam@ico.unicancer.fr
Study Contact Backup
- Name: Valentine GUIMAS, MD
- Phone Number: +33 (0)240679916
- Email: valentine.guimas@ico.unicancer.fr
Study Locations
-
-
-
Angers, France, 49055
- Recruiting
- Institut de Cancérologie de l'Ouest
-
Contact:
- Nathalie MESGOUEZ-NEBOUT, MD
- Phone Number: +33(0)241352912
- Email: nathalie.mesgouez-nebout@ico.unicancer.fr
-
Principal Investigator:
- Nathalie MESGOUEZ-NEBOUT, MD
-
Brest, France, 29200
- Recruiting
- CHRU de Brest - Hopital Morvan
-
Contact:
- Ulrike SCHICK, MD
- Phone Number: +33(0)2 98 22 33 33
- Email: ulrike.schick@chu-brest.fr
-
Principal Investigator:
- Ulrike SCHICK, MD
-
Chambray-lès-Tours, France, 37170
- Not yet recruiting
- Societe de Recherche Oncologique Clinique 37 (Roc 37)
-
Contact:
- Thomas BOISSERIE, MD
- Email: t.boisserie@cort37.fr
-
Principal Investigator:
- Thomas BOISSERIE, MD
-
Dijon, France, 21079
- Not yet recruiting
- Centre Georges François Leclerc
-
Contact:
- Magali QUIVRIN, MD
- Phone Number: +33(0)3 80 73 75 18
- Email: mquivrin@cgfl.fr
-
Principal Investigator:
- Magali QUIVRIN, MD
-
Le Mans, France, 72100
- Not yet recruiting
- Clinique Victor Hugo
-
Contact:
- Amandine RUFFIER LOUBIERE, MD
- Email: essaisruffier@ilcgroupe.fr
-
Principal Investigator:
- Amandine RUFFIER LOUBIERE, MD
-
Lille, France, 59020
- Recruiting
- Centre Oscar Lambret
-
Contact:
- David PASQUIER, MD
- Phone Number: +33(0)320295911
- Email: d-pasquier@o-lambret.fr
-
Principal Investigator:
- David PASQUIER, MD
-
Lyon, France, 69373
- Recruiting
- Centre Leon Berard
-
Principal Investigator:
- Pascal POMMIER
-
Contact:
- Pascal POMMIER, MD
- Phone Number: +33(0)4 78 78 28 28
- Email: pascal.pommier@lyon.unicancer.fr
-
Rennes, France, 35042
- Not yet recruiting
- Centre Eugène Marquis
-
Contact:
- Renaud DE CREVOISIER, MD
- Phone Number: +33(0)2 99 63 91 78
- Email: r.de-crevoisier@rennes.unicancer.fr
-
Principal Investigator:
- Renaud DE CREVOISIER, MD
-
Rouen, France, 76038
- Not yet recruiting
- Centre Henri Becquerel
-
Contact:
- Maximilien ROGE, MD
- Email: maximilien.roge@chb.unicancer.fr
-
Principal Investigator:
- Maximilien ROGE, MD
-
Saint Herblain, France, 44805
- Recruiting
- Institut de Cancérologie de l'Ouest
-
Contact:
- Valentine GUIMAS, MD
- Phone Number: +33 (0)240679916
- Email: valentine.guimas@ico.unicancer.fr
-
Principal Investigator:
- Valentine GUIMAS, MD
-
Strasbourg, France, 67200
- Recruiting
- ICANS - Institut de cancérologie Strasbourg Europe
-
Contact:
- Jean-Baptiste Jean-Baptiste, MD
- Email: jb.clavier@icans.eu
-
Principal Investigator:
- Jean-Baptiste Jean-Baptiste, MD
-
Tours, France, 37044
- Not yet recruiting
- CHRU Bretonneau
-
Contact:
- Gilles CALAIS, MD
- Phone Number: +33(0)2 47 47 82 65
- Email: gilles.calais@univ-tours.fr
-
Principal Investigator:
- Gilles CALAIS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written informed consent according to International Conference on Harmonisation (ICH)/ Good Clinical Practice (GCP) regulations before registration and prior to any trial specific procedures.
- Biochemical recurrence occurring at least 2 years after external radiotherapy to the prostate lodge and the end of hormone therapy, for prostatic adenocarcinoma previously treated by radical prostatectomy.
- Local recurrence in irradiated areas proven by biological (PSA > 0.2 ng/ml and ascending confirmed by at least 2 successive assays) and radiological (lesion visible on MRI and/or Choline PET and/or Prostate-Specific Membrane Antigen (PSMA) PET).
- Recurrence without rectal invasion
- Pelvic and prostate MRI evaluation
- Absence of pelvic lymph node or metastatic recurrence proven by choline PET or PSMA PET scan
- World Health Organisation (WHO) performance status 0-1
- Low risk, intermediate risk and high risk with a single risk factor
- PSA doubling time > 6 months
- No anti-cancer treatments planned for the current relapse, including hormone therapy.
- Age > 18 years old.
- Life expectancy greater than or equal to 5 years.
- Patient registered with a health insurance system.
- Patients willing and able to comply with the planned visits, treatment plan, laboratory tests and other study procedures indicated in the protocol.
Exclusion Criteria:
- Metastatic disease (bone, lymph node or other)
- Late radiotherapy urinary or gastrointestinal toxicity (grade ≥ 2) (after radiotherapy of prostate lodge)
- History of cancer in the 5 years prior to trial entry other than cutaneous basal cell carcinoma
- Inflammatory bowel disease
- Contraindications for performing MRI
- Rectal surgery history
- Patient treated for Diabetes
- Creatinine clearance < 45 mL/min
- Treatment with metformin in the last 3 months prior to inclusion
Severe comorbidity that may affect treatment, for example :
- Acute bacterial or fungal infection requiring intravenous antibiotics at the time of inclusion.
- Unstable angina, myocardial infarction and/or congestive heart failure requiring hospitalization within the last 6 months
- Myocardial infarction in the last 6 months.
- Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) or other respiratory conditions requiring hospitalization or preventing metformin therapy at the time of inclusion.
- Any condition associated with an increased risk of lactic acidosis (e.g., alcohol abuse, New York Heart Association (NYHA) III or IV congestive heart failure).
- Clinically significant history of hepatopathy with Child-Pugh B or C score, including viral infection or hepatitis, alcohol abuse or cirrhosis.
- Any acute or chronic condition that may result in tissue hypoxia (e.g. heart or respiratory failure, shock).
- Bilateral hip prosthesis
- Treatment with any investigational drug or participation in a clinical trial within 30 days prior to inclusion.
- Known hypersensitivity to metformin or any of its components
- Inability or reluctance to swallow oral medications
- Persons deprived of liberty, under a measure of safeguard of justice, under guardianship or under the tutor authority
- Inability to undergo medical monitoring of the trial for geographical, social or psychological reasons.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Metformin + SBRT at total dose of 30 Gray (Gy)
Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75) Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5 x 6 Gy, (day 0 to day 10) |
Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)
Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5 x 6 Gy day 0 to day 10
Other Names:
|
Experimental: Metformin + SBRT at total dose of 36 Gy
Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75) Stereotactic Body Radiation Therapy (SBRT): Dose escalation 6 x 6 Gy (day 0 to day 12) |
Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)
Stereotactic Body Radiation Therapy (SBRT): Dose escalation 6 x 6 Gy day 0 to day 12
Other Names:
|
Experimental: Metformin + SBRT at total dose of 25 Gy
Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75) Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5 x 5 Gy (day 0 to day 10) |
Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)
Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5x 5 Gy day 0 to day 10
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
For phase 1:. Select the recommended dose for SBRT (either 5 x 6 Gy, 6 x 6 Gy, or 5 x 5 Gy), in combination with Metformin
Time Frame: 12 weeks
|
SBRT toxicity will be reported during the 12 weeks following the initiation of SBRT.
|
12 weeks
|
For phase 2: estimate the efficacy of re-irradiation SBRT in combination with Metformin in terms of biochemical relapse-free survival rate.
Time Frame: 3 years
|
PSA levels will be assessed every 3 months within 3 years after SBRT.
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Estimate the efficacy of re-irradiation SBRT in combination with Metformin in terms of biochemical relapse-free survival and biochemical response
Time Frame: 5 years
|
PSA levels will be assessed every 3 months within 5 years after SBRT. For all patients, visits will be made at 6, 9, 12, 18, 24, 36 months, 4 years, and 5 years will be made from the start of SBRT. The end of the trial is defined by the last visit of the last included patient. |
5 years
|
Estimation of the efficacy of SBRT re-irradiation in combination with Metformin in terms of progression-free survival and overall survival
Time Frame: 5 years
|
Clinical progression-free survival is defined as the time interval between the date of SBRT start and the date of clinical progression (local progression assessed by the physical examination, or appearance of metastatic lesions), start of hormonal therapy or death irrespective of the cause.
|
5 years
|
Evaluation of acute and late genitourinary and gastrointestinal toxicities of the SBRT re-irradiation
Time Frame: 5 years
|
Acute and late genitourinary toxicities over the first 5 years will be assessed according to the NCI-CTCAE V5.0 classification
|
5 years
|
Evaluation of Quality of life after SBRT re-irradiation in combination with Metformin
Time Frame: 5 years
|
Quality of life will be assessed based on EORTC Quality of life questionnaire (QLQ)-C30 scale at week 4; 8; 12; and month M6; M9; M12; M18; M24; M36; 4 years and 5 years.
The Time Until Definitive Deterioration (TUDD) will be computed from registration until the first observation of a definitive deterioration of the quality of life, defined as a score decreased by 10 points (in the case of global health scale and functional scales) or increased by 10 points (in the case of symptom scales) compared to the score at baseline, without later improvement superior to 10 points compared to baseline score.
|
5 years
|
Evaluation of Quality of life after SBRT re-irradiation in combination with Metformin
Time Frame: 5 years
|
Quality of life will be assessed based on EORTC Quality of life questionnaire in prostate cancer (QLQ-PR25) scale at week 4; 8; 12; and month M6; M9; M12; M18; M24; M36; 4 years and 5 years.
The Time Until Definitive Deterioration (TUDD) will be computed from registration until the first observation of a definitive deterioration of the quality of life, defined as a score decreased by 10 points (in the case of global health scale and functional scales) or increased by 10 points (in the case of symptom scales) compared to the score at baseline, without later improvement superior to 10 points compared to baseline score.
|
5 years
|
Evaluation of erectile function
Time Frame: 5 years
|
Erectile function will be assessed by International Index of Erectile Function (IIEF5). This score assesses erectile function over the past 6 months on a scale of 1 to 25 (total of 5 items rated 0/1 to 5). The distributions of this score will be described at baseline, at follow-up visits (M6 M12 M18, M24,M36 4 and 5 years old) and at the end of the study visit according to the following categories: 1 - 4: Non-interpretable ; 5 - 10: Severe erectile dysfunction ; 11 - 15: Moderate erectile dysfunction ; 16 - 20: Mild erectile dysfunction ; 21 - 25: Normal erectile function. |
5 years
|
Evaluation of urinary symptoms
Time Frame: 5 years
|
Urinary symptoms over the first 5 years will be assessed by International Prostatic Symptom Score (IPSS). This score evaluates the severity of prostate symptoms in the last month on a scale of 0 to 35 (total of 7 items rated 0 to 5).The distributions of this score will be described at inclusion, at follow-up visits (M6 M9 M12 M18 M24 M36 4 and 5 years) and at the end of the study visit according to the following categories: 0 - 7: Poorly symptomatic ; 8 - 19: Moderately symptomatic ; 20 - 35: Severe symptoms. |
5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Valentine GUIMAS, MD, Institut de Cancérologie de l'Ouest
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ICO-2020-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedProstate Adenocarcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on Metformin
-
Anji PharmaSuspendedDiabetes Mellitus, Type 2Spain, United States, Canada, Hungary, Brazil, Czechia, Poland, Bulgaria
-
ShionogiCompleted
-
NuSirt BiopharmaCompletedType 2 Diabetes MellitusUnited States
-
Charles University, Czech RepublicCompleted
-
Bristol-Myers SquibbCompletedType 2 Diabetes MellitusSouth Africa, United States, Canada, Puerto Rico, Hungary, Germany, Czechia, Poland, Romania, United Kingdom
-
Woman'sPfizer; American Cancer Society, Inc.; Our Lady of the Lake Regional Medical...WithdrawnInsulin Resistance | Breast Cancer Stage | Racial BiasUnited States
-
Hoffmann-La RocheCompletedDiabetes Mellitus Type 2United States, Mexico, Argentina
-
Hadassah Medical OrganizationWithdrawn
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
University Hospital, Basel, SwitzerlandCompletedBecker's Muscular Dystrophy (BMD)Switzerland